A new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Dol Gleizes, Frédérique ^a   Delesque Touchard, Nathalie ^a   Marès, Anne Marie ^a   Nestor, Anne Laure ^a   Schaeffer, Paul ^a   Bono, Françoise ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; APOLIPOPROTEIN E; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; LIPID; SSR 128129E; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SINUS; ARTERIOSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; GENE EXPRESSION; LIPID BLOOD LEVEL; MALE; MOUSE; NEOINTIMA; NONHUMAN; TREATMENT OUTCOME; VEIN GRAFT;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, FIBROBLAST GROWTH FACTOR; VEINS;

EID: 84891839599     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080027     Document Type: Article

References (37)

1. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695. doi:10.1056/NEJMra043430. PubMed: 15843671.
2. Toutouzas K, Colombo A, Stefanadis C (2004) Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 25: 1679-1687. doi:10.1016/j.ehj.2004.06.011. PubMed: 15451145.
3. Gerszten RE, Mach F, Sauty A, Rosenzweig A, Luster AD (2000) Chemokines, leukocytes, and atherosclerosis. J Lab Clin Med 136: 87-92. doi:10.1067/mlc. 2000.108154. PubMed: 10945236.
4. Weber C (2005) Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 96: 612-616. doi:10.1161/01.RES.0000160077.17427.57. PubMed: 15802619.
5. Brogi E, Winkles JA, Underwood R, Clinton SK, Alberts GF et al. (1993) Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. Association of acidic FGF with plaque microvessels and macrophages. J Clin Invest 92: 2408-2418. doi:10.1172/JCI116847. PubMed: 7693761.
6. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R (2010) Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 30: 1282-1292. doi:10.1161/ATVBAHA.108.179739. PubMed: 20554950.
7. Khurana R, Simons M, Martin JF, Zachary IC (2005) Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 112: 1813-1824. doi:10.1161/CIRCULATIONAHA.105.535294. PubMed: 16172288.
8. Sluimer JC, Daemen MJ (2009) Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol 218: 7-29. doi: 10.1002/path.2518. PubMed: 19309025.
9. Cheng C, Chrifi I, Pasterkamp G, Duckers HJ (2013) Biological mechanisms of microvessel formation in advanced atherosclerosis: The big Five. Trends Cardiovasc Med 23: 153-164. doi:10.1016/j.tcm.2012.10.004. PubMed: 23375379.
10. Lindner V, Reidy MA (1991) Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A 88: 3739-3743. doi:10.1073/pnas.88.9.3739. PubMed: 2023924.
11. Luo W, Liu A, Chen Y, Lim HM, Marshall-Neff J et al. (2004) Inhibition of accelerated graft arteriosclerosis by gene transfer of soluble fibroblast growth factor receptor-1 in rat aortic transplants. Arterioscler Thromb Vasc Biol 24: 1081-1086. doi:10.1161/01.ATV.0000128201.65443.ea. PubMed: 15072997.
12. Che J, Okigaki M, Takahashi T, Katsume A, Adachi Y et al. (2011) Endothelial FGF receptor signaling accelerates atherosclerosis. Am J Physiol Heart Circ Physiol 300: H154-H161. doi:10.1152/ajpheart.00075.2010. PubMed: 20952669.
13. Raj T, Kanellakis P, Pomilio G, Jennings G, Bobik A et al. (2006) Inhibition of fibroblast growth factor receptor signaling attenuates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 26: 1845-1851. doi:10.1161/01.ATV.0000227689.41288.5e. PubMed: 16709940.
14. Sun L, Tran N, Liang C, Tang F, Rice A et al. (1999) Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl] indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem 42: 5120-5130. doi:10.1021/jm9904295. PubMed: 10602697.
15. Petrovan RJ, Kaplan CD, Reisfeld RA, Curtiss LK (2007) DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 27: 1095-1100. doi:10.1161/ATVBAHA.106.139246. PubMed: 17303776.
16. Hauer AD, van Puijvelde GH, Peterse N, de VP, van W, et al V. (2007) Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 27: 2050-2057. doi:10.1161/ATVBAHA.107.143743. PubMed: 17600223.
17. Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M et al. (2013) Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties. Cancer Cell 23: 477-488. doi:10.1016/j.ccr.2013.02.019. PubMed: 23597562.
18. Zou Y, Dietrich H, Hu Y, Metzler B, Wick G et al. (1998) Mouse model of venous bypass graft arteriosclerosis. Am J Pathol 153: 1301-1310. doi:10.1016/S0002-9440(10)65675-1. PubMed: 9777962.
19. Ganter P, Jollès G (1970) Histochimie normale et pathologique. In: Gauthier-Villars. p. 1420.
20. Dol F, Martin G, Staels B, Mares AM, Cazaubon C et al. (2001) Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 38: 395-405. doi:10.1097/00005344-200109000-00008. PubMed: 11486244.
21. Fons P, Herault JP, Delesque N, Tuyaret J, Bono F et al. (2004) VEGFR2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells. J Cell Physiol 200: 351-359. doi: 10.1002/jcp.20076. PubMed: 15254962.
22. Higuchi R, Fockler C, Dollinger G, Watson R (1993) Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (N Y) 11: 1026-1030.
23. Flugelman MY, Virmani R, Correa R, Yu ZX, Farb A et al. (1993) Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina. A clue to the mechanism of transformation from the stable to the unstable clinical state. Circulation 88: 2493-2500. doi:10.1161/01.CIR.88.6.2493. PubMed: 7504590.
24. Libby P (1995) Molecular bases of the acute coronary syndromes. Circulation 91: 2844-2850. doi:10.1161/01.CIR.91.11.2844. PubMed: 7758192.
25. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ (2005) Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 46: 937-954. doi:10.1016/j.jacc.2005.03.074. PubMed: 16168274.
26. Fox JC, Shanley JR (1996) Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells. J Biol Chem 271: 12578-12584. doi:10.1074/jbc.271.21.12578. PubMed: 8647868.
27. Geng YJ, Libby P (2002) Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol 22: 1370-1380. doi:10.1161/01.ATV.0000031341.84618.A4. PubMed: 12231554.
28. Kavurma MM, Bhindi R, Lowe HC, Chesterman C, Khachigian LM (2005) Vessel wall apoptosis and atherosclerotic plaque instability. J Thromb Haemost 3: 465-472. doi:10.1111/j.1538-7836.2005.01120.x. PubMed: 15748235.
29. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P et al. (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276: 955-960. doi:10.1126/science.276.5314.955. PubMed: 9139660.
30. Xu Q (2004) Mouse models of arteriosclerosis: from arterial injuries to vascular grafts. Am J Pathol 165: 1-10. doi:10.1016/S0002-9440(10)63270-1. PubMed: 15215157.
31. Zittermann SI, Issekutz AC (2006) Basic Fibroblast Growth Factor (bFGF, FGF-2) Potentiates Leukocyte Recruitment to Inflammation by Enhancing Endothelial Adhesion Molecule Expression. Am J Pathol 168: 835-846. doi:10.2353/ajpath.2006.050479. PubMed: 16507899.
32. Dell'Era P, Ronca R, Coco L, Nicoli S, Metra M et al. (2003) Fibroblast growth factor receptor-1 is essential for in vitro cardiomyocyte development. Circ Res 93: 414-420. doi:10.1161/01.RES.0000089460.12061.E1. PubMed: 12893744.
33. Speir E, Tanner V, Gonzalez AM, Farris J, Baird A et al. (1992) Acidic and basic fibroblast growth factors in adult rat heart myocytes. Localization, regulation in culture, and effects on DNA synthesis. Circ Res 71: 251-259. doi:10.1161/01.RES.71.2.251. PubMed: 1378359.
34. Jimenez SK, Sheikh F, Jin Y, Detillieux KA, Dhaliwal J et al. (2004) Transcriptional regulation of FGF-2 gene expression in cardiac myocytes. Cardiovasc Res 62: 548-557. doi:10.1016/j.cardiores.2004.01.032. PubMed: 15158147.
35. Martin G, Dol F, Marés AM, Berezowski V, Staels B et al. (2004) Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan. J Cardiovasc Pharmacol 43: 191-199. doi:10.1097/00005344-200402000-00005. PubMed: 14716205.
36. Herrmann J, Lerman LO, Mukhopadhyay D, Napoli C, Lerman A (2006) Angiogenesis in atherogenesis. Arterioscler Thromb Vasc Biol 26: 1948-1957. doi:10.1161/01.ATV.0000233387.90257.9b. PubMed: 16794218.
37. Hao H, Gabbiani G, Bochaton-Piallat ML (2003) Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol 23: 1510-1520. doi:10.1161/01.ATV.0000090130. 85752.ED. PubMed: 12907463.